Sagopilone

Drug Profile

Sagopilone

Alternative Names: BAY86-5302; SH Y03757A; SHY-03757; ZK 219477; ZK epothilone; ZK-EPO

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antineoplastics; Epothilones
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 18 Dec 2009 Interim adverse events and pharmacokinetics data from a phase I trial in solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
  • 30 Sep 2008 Efficacy and adverse events data from a phase II trial in metastatic prostate cancer, non-small cell lung cancer and ovarian cancer presented at the 33rd Congress of the European Society for Medical Oncology (ESMO-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top